News Releases

March 14, 2017

RepliCel’s Phase 1 Clinical Trial For Hair Loss Succeeds In Meeting Primary Endpoints
Five-year safety data firmly establishes product safety and confirms ongoing clinical and product development strategy VANCOUVER, BC – March 14, 2017 – RepliCel Life... Read full article

March 7, 2017

RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization
VANCOUVER, BC – March 7, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel” or the “Company”), a clinical stage regenerative medicine company... Read full article

March 6, 2017

RepliCel Life Sciences Announces Re-pricing of Warrants
VANCOUVER, BC – March 6, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”) (OTCQB: REPCD) (TSX.V: RP) (Frankfurt: P6P2), a clinical stage... Read full article

February 28, 2017

RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector
Two European firms team up to lead RepliCel’s next-generation dermal injector (RCI-02) to market-ready status VANCOUVER, BC – February 28, 2017 – RepliCel Life... Read full article

February 24, 2017

RepliCel Life Sciences Announces Closing of Brokered and Non-brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC – February 24, 2017 – RepliCel... Read full article

February 9, 2017

RepliCel Announces European Patents for its Innovative Dermal Injector Technologies
RCI-02, RepliCel’s nearest-term commercial asset, enables game-changing reliability, reproducibility, and programmability of three-dimensional skin injections  VANCOUVER, BC – February 9, 2017 – RepliCel Life... Read full article

February 7, 2017

Replicel Life Sciences Inc. Announces Brokered Private Placement
VANCOUVER, BC – February 7, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”) (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine... Read full article

February 3, 2017

RepliCel Appoints Corporate Executive, Hugh Rogers to its Board of Directors
VANCOUVER, BC – February 3, 2017 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (“RepliCel” or the “Company”) is pleased to announce the... Read full article

January 4, 2017

RepliCel CEO Provides 2017 Forecast
After a year of restructuring, RepliCel poised for multiple clinical trial data announcements and completion of medical device prototypes VANCOUVER, BC – January 5,... Read full article